Skip to main content

Advertisement

SpringerLink
Log in

Pharmacology of benzydamine

  • Review
  • Published:
InflammoPharmacology Aims and scope Submit manuscript

Abstract

Benzydamine is a topical anti-inflammatory drug which is widely available and used topically for the treatment of the mouth. It is also used as a gel for application to inflamed joints. It has physicochemical properties and pharmacological activities which differ markedly from those of the aspirin-line non-steroidal anti-inflammatory drugs. Benzydamine is a weak base unlike the aspirin-like drugs which are acids or metabolized to acids. A major contrast with the aspirin-like drugs is that benzydamine is a weak inhibitor of the synthesis of prostaglandins but it has several properties which may contribute to its anti-inflammatory activity. These properties include inhibition of the synthesis of the inflammatory cytokine, tumour necrosis factor-α (EC50, 25 µmol/L). Inhibition of the oxidative burst of neutrophils occurs under some conditions at concentrations of 30 to 100 µmol/L, concentrations which may be produced within oral tissues after local application. A further activity of benzydamine is a general activity known as membrane stabilization which is demonstrated by several actions including inhibition of granule release from neutrophils at concentrations ranging from 3 to 30 µmol/L and stabilization of lysosomes. Lack of knowledge of the tissue concentrations of benzydamine limit the correlation between pharmacological activities in vitro and in vivo. The concentration of benzydamine in the mouthwash is 4 mmol/L but the concentrations in oral tissues have not been studied adequately. Limited data in the rat indicates that concentrations of benzydamine in oral tissues are approximately 100 µmol/L.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Silvestrini B, Scorza Barcellona P, Garau A, Catanese B. Toxicology of benzydamine. Toxicol Appl Pharmacol. 1967;10:148–59.

    Article  PubMed  CAS  Google Scholar 

  2. Hansch C, Sammes PG, Taylor JB. In: Drayton CJ, ed. Comprehensive Medicinal Chemistry, Volume 6. Oxford: Pergamon Press; 1990:309.

    Google Scholar 

  3. Jez JM, Vanderkooi JM, Laties AM. Spectroscopic characterization of benzdazac and benzydamine: possible photochemical modes of action. Biochem Biophys Res Commun. 1996;221:266–70.

    Article  PubMed  CAS  Google Scholar 

  4. Baldock GA, Brodie RR, Chasseaud LF, Taylor T, Walmsley LM, Catanese B. Pharmacokinetics of benzydamine after intravenous, oral, and topical doses to human subjects. Biopharm Drug Dispos. 1991;12:481–92.

    Article  PubMed  CAS  Google Scholar 

  5. Schoenwald RD, Kumakura T, Catanese B. Pharmacokinetics of benzydamine. Int J Tiss React. 1987;9:9–7.

    Google Scholar 

  6. Beckett AH, Triggs EJ. Buccal absorption of basic drugs and its application as an in vivo model of passive drug transfer through lipid membranes. J Pharm Pharmacol. 1967;19:31S-41S.

    PubMed  Google Scholar 

  7. Bickel MH, Weder HJ. Buccal absorption and other properties of pharmacokinetic importance of imipramine and its metabolites. J Pharm Pharmacol. 1969;21:160–8.

    PubMed  CAS  Google Scholar 

  8. Chasseaud LF, Catanese B. Pharmacokinetics of benzydamine. Int J Tiss React. 1985;7:195–204.

    CAS  Google Scholar 

  9. Andersson K, Larsson H. Percutaneous absorption of benzydamine in guinea pig and man. Arzneimittelforschung. 1974;24:1686–8.

    PubMed  CAS  Google Scholar 

  10. Lisciani R, Scorza Barcellona P, Silvestrini B. Researches on the topical activity of benzydamine. Eur J Pharmacol. 1968;3:157–62.

    Article  PubMed  CAS  Google Scholar 

  11. Giacalone E, Valzelli L. A method for the determination of 1-benzyl-3[3′-(dimethylamino) propoxy]-1H-indazole (benzydamine) in rat tissues. Med Pharmacol Exp. 1966;15:102–6.

    CAS  Google Scholar 

  12. Kataoka S, Nishimura K, Naito T. In vivo metabolism and anti-inflammatory activity of benzydamine hydrochloride in rats treated with carrageenin. Chem Pharm Bull (Tokyo). 1979;27:2890–903.

    CAS  Google Scholar 

  13. Catanese B, Lisciani R, Piccinelli D. Erythrocyte membrane stabilization and protein binding of some anti-inflammatory drugs and of deoxycholic acid. Biochem Pharmacol. 1969;18:1707–10.

    Article  PubMed  CAS  Google Scholar 

  14. Benedetto A, Cassone A, Amici C, Garaci E. Enhanced uptake of actinomycin D in cultured mammalian cells by the anti-inflammatory non-steroidal drug benzydamine. Biochem Pharmacol. 1979;28:2723–8.

    Article  PubMed  CAS  Google Scholar 

  15. Catanese B, Grasso A, Silvestrini B. Studies on the absorption and elimination of benzydamine in the mouse, rat, dog and man. Arzneimittelforschung. 1985;35:634–5.

    Google Scholar 

  16. Köppel C, Tenczer. Metabolism of benzydamine. Arzneimittelforschung. 1985;35:634–5.

    PubMed  Google Scholar 

  17. Fanaki NH, El-Nakeeb MA. Antibacterial activity of benzydamine and antibiotic-benzydamine combinations against multifold resistant clinical isolates. Arzneimittelforschung. 1996;46:320–3.

    PubMed  CAS  Google Scholar 

  18. Fanaki NH, el-Nakeeb MA. Antimicrobial activity of benzydamine, a non-steroid anti-inflammatory agent. J Chemother. 1992;4:347–52.

    PubMed  CAS  Google Scholar 

  19. White SK. The pharmacology of benzydamine. Res Clin Forums. 1988;10:8–23.

    Google Scholar 

  20. Boissier JR, Lwoff JM, Hertz F. Action comparee de six anti-inflammatory non steroidiques. Therapie. 1970;25:43–60.

    PubMed  CAS  Google Scholar 

  21. Yamatake Y, Kato H, Takagi K. Effects of vasoactive agents on the canine forelimb venous perfusion preparation and their modification by anti-inflammatory drugs. Jpn J Pharmacol. 1975;25:129–39.

    CAS  Google Scholar 

  22. Fantato S, De Gregorio M. Clinical evaluation of topical benzydamine in traumatology. Arzneimittelforschung. 1971;21:1530–3.

    PubMed  CAS  Google Scholar 

  23. Chatterjee DS. A double blind clinical study with benzydamine 3% on soft tissue injuries in an occupational health centre. J Int Med Res. 1977;5:450–8.

    PubMed  CAS  Google Scholar 

  24. Froom J, Boisseau V. Benzydamine oral rinse for sore throat. Curr Ther Res. 1979;26:856–61.

    Google Scholar 

  25. Whiteside MW. A controlled study of benzydamine oral rinse (“Difflam”) in general practice. Curr Med Res Opin. 1982;8:188–90.

    PubMed  CAS  Google Scholar 

  26. Epstein JB, Stevenson-Moore P. Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy. Oral Surg Oral Med Oral Pathol. 1986;62:145–8.

    Article  PubMed  CAS  Google Scholar 

  27. Sonis ST, Clairmont ST, Lockhart PB, Connolly SF. Benzydamine HCl in the management of chemotherapy-induced mucositis. I. Pilot study. J Oral Med. 1985;40:67–71.

    PubMed  CAS  Google Scholar 

  28. Valijan A. Pain relief after tonsillectomy. Anaesthesia. 1989;44:990–1.

    Article  PubMed  CAS  Google Scholar 

  29. Matthews RW, Scully CM, Levers BGH. Clinical evaluation of benzydamine, chlorohexidine, and placebo mouthwashes in the management of recurrent aphthous stomatis. Oral Surg Oral Med Oral Pathol. 1987;63:189–91.

    Article  PubMed  CAS  Google Scholar 

  30. Hunter KMacD. A clinical evaluation of benzydamine hydrochloride. Aust Dent J. 1978;23:164–6.

    PubMed  CAS  Google Scholar 

  31. Adame Sosa R, Gomez Pedroso A. Evaluation of benzydamine in treatment of secondary inflammation following extraction of third molars. Pract Odontol. 1990;11:29–31.

    PubMed  CAS  Google Scholar 

  32. Tomazzoli L, Bonora MR, Luparini L, Durando MG, Ciolo V, Bonomi L. Effects of benzydamine on the rabbit’s eye reaction to surgical, physical and chemical stimuli. J Ocul Pharmacol. 1989;5:71–80.

    Article  PubMed  CAS  Google Scholar 

  33. Saeed SA, Kendall PA, Butt NM, Collier HOJ. On the mode of action and biochemical properties of anti-inflammatory drugs. Biochem Soc Trans. 1979;7:655–7.

    PubMed  CAS  Google Scholar 

  34. Müller-Peddinghaus R, Wurl M, Lenoir G, Houben A, Remacle J. Einfluss von benzydamin auf bildung ung interacktion von reaktiven sauerstoffspezies und die zyklo- und lipoxigenase. Arzneimittelforschung. 1987;37:601–5.

    PubMed  Google Scholar 

  35. Segre G, Hammarström S. Aspects of the mechanisms of action of benzydamine. Int J Tiss React. 1985;7:187–93.

    CAS  Google Scholar 

  36. Rang HP, Dale MM, Ritter JM. In: Pharmacology, 3rd edn. Edinburgh: Churchill Livingstone; 1995:230.

    Google Scholar 

  37. Löffler BM, Bohn E, Hesse B, Kunze H. The action of benzydamine on phospholipase activation. Arzneimittelforschung. 1987;37:618–21.

    PubMed  Google Scholar 

  38. Moncada S, Needleman P, Bunting S, Vane JR. Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition. Prostaglandins. 1976;12:323–35.

    Article  PubMed  CAS  Google Scholar 

  39. Diczfalusy U, Hammarström S. Inhibitors of thromboxane synthase in human platelets. FEBS Lett. 1977;82:107–10.

    Article  CAS  Google Scholar 

  40. Jansen WCM. Antithrombotische wirking von benzydamin. Arzneimittelforschung. 1987;37:626–8.

    PubMed  CAS  Google Scholar 

  41. Flower RJ, Cheung HS, Cushman DW. Quantitative determination of prostaglandins and malondialdehyde formed by the arachidonic oxygenase (prostaglandin synthetase) system of bovine seminal vesicle. Prostaglandins. 1973;4:325–41.

    Article  PubMed  CAS  Google Scholar 

  42. Dinnendahl V, Peters HD, Schönhöfer PS. Effects of benzydamine on the lipolytic system of fat cells. Biochem Pharmacol. 1976;25:299–303.

    Article  PubMed  CAS  Google Scholar 

  43. Akamatsu M, Miura Y. Inhibition of amino sugar formation by several non-steroid anti-inflammatory agents. Biochem Pharmacol. 1972;21:1991–3.

    Article  PubMed  CAS  Google Scholar 

  44. Baggiolini M, Mauderli P, Näf U, Catanese B. Effect of benzydamine on exocytosis and respiratory burst in human neutrophils and mononuclear phagocytes. Agents Actions. 1985;16:346–52.

    Article  PubMed  CAS  Google Scholar 

  45. Sironi M, Pozzi P, Polentarutti N et al. Inhibition of inflammatory cytokine production and protection against endotoxin toxicity by benzydamine. Cytokines. 1996;8:710–16.

    Article  CAS  Google Scholar 

  46. Müller-Peddinghaus R, Wurl M. The amplified chemiluminescence test to characterize antirheumatic drugs as oxygen radical scavengers. Biochem Pharmacol. 1987;36:1125–32.

    Article  PubMed  Google Scholar 

  47. Oyanagui Y. Inhibition of superoxide anion production in macrophages by anti-inflammatory drugs. Biochem Pharmacol. 1976;25:1473–80.

    Article  PubMed  CAS  Google Scholar 

  48. Silvestrini B, Garau A, Pozzatti C, Cioli V, Catanese B. Additional pharmacological studies on benzydamine. Arch Int Pharmacodyn Ther. 1966;163:61–9.

    PubMed  CAS  Google Scholar 

  49. Simard-Savoie S, Forest D. Topical anaesthetic activity of benzydamine. Curr Ther Res. 1978;6:734–5.

    Google Scholar 

  50. Cioli V, Corradino C, Scorza Barcellona P. Review of pharmacological data on benzydamine. Int J Tiss React. 1985;8:205–13.

    Google Scholar 

  51. Buritova J, Fletcher D, Honore P, Besson J-M. Effects of local anaesthetics on carrageenan-evoked inflammatory nocioceptive processing in the rat. Br J Anaesth. 1996;77:645–52.

    PubMed  CAS  Google Scholar 

  52. Pedersen JL, Callesen T, Moiniche S, Kehlet H. Analgesic and anti-inflammatory effects of lignocaine-prilocaine (EMLA) cream in human burn injury. Br J Anaesth. 1996;76:806–10.

    PubMed  CAS  Google Scholar 

  53. Goto K, Hisadome M, Imamura H. Effects of tinoridine on stability of rat liver and kidney lysosomes and liver parenchymal cells. Biochem Pharmacol. 1977;26:11–18.

    Article  PubMed  CAS  Google Scholar 

  54. Irita K, Fujita I, Takeshige S, Minakami S, Yoshitake J. Cinchocaine and amethocaine inhibit activation and activity of superoxide production of human neutrophils. Br J Anaesth. 1986;58:639–45.

    Article  PubMed  CAS  Google Scholar 

  55. Anderson R, Ramafi G, Theron AJ. Membrane stabilizing anti-oxidative interactions of propranolol and dexpropranolol with neutrophils. Biochem Pharmacol. 1996;52:341–9.

    Article  PubMed  CAS  Google Scholar 

  56. Neal TM, Vissers MC, Winterbourn CC. Inhibition of nonsteroidal anti-inflammatory drugs of superoxide production and granule enzyme release by polymorphonuclear leukocytes stimulated with immune complexes or formyl-methionyl-leucyl-phenylalanine. Biochem Pharmacol. 1987;36:2511–17.

    Article  PubMed  CAS  Google Scholar 

  57. Neal TM, Vissers MC, Winterbourn CC. Inhibition of neutrophil-mediated degradation of isolated basement membrane collagen by nonsteroidal antiinflammatory drugs that inhibit degranulation. Arthritis Rheum. 1987;30:908–13.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Physiology and Pharmacology, University of NSW, 2052, Sydney, Australia

    P. A. Quane & G. G. Graham

  2. School of Paediatrics, University of NSW, 2052, Sydney, Australia

    J. B. Ziegler

Authors
  1. P. A. Quane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. G. Graham
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. B. Ziegler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Quane, P.A., Graham, G.G. & Ziegler, J.B. Pharmacology of benzydamine. Inflammopharmacol 6, 95–107 (1998). https://doi.org/10.1007/s10787-998-0026-0

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10787-998-0026-0

Keywords

Search

Navigation